OnabotulinumtoxinA in the treatment of refractory chronic cluster headache

Table 2 Demographic details, headache scores pre- and post- treatment with OnabotulinumtoxinA

patients ID	duration/y	baseline		treatment phase					patient subjective estimate of response %^b
		frequency d/mo	duration min	week 12		week 24		improvement %^b
		frequency d/mo	duration min	frequency d/mo^a	sum of min/ bout^a	frequency d/mo^a	sum of min bout^a	improvement %^b
1	7	30	2.250	17	1.755	14	1.320	41.3	50
2	4	25	1.632	8	337	0	0	100	90–100
3	3	28	1.328	11	472	7	221	83.3	60–70
4	5	29	2.598	0	0	0	0	100	100
5	5	30	3.148	12	1.065	8	531	83.1	75
6	5	30	1.912	8	867	5	312	83,6	70
7	9	28	2.491	12	1.289	7	1.333	46.4	50
8	7	30	1.870	8	473	6	328	82.4	70–80
9	7	25	1.140	13	833	11	618	45.8	50
10	4	27	3.456	14	2.855	12	1.565	54.7	50
11	3	30	1.080	30	1.418	30	1.377	0	0
12	3	30	3.020	16	1.844	14	813	73	50
13	3	30	2.280	29	2.065	30	2.555	0	0
14	6	28	1.680	0	0	0	0	100	100
15	4	27	2.479	18	1.349	22	1.662	32,9	20–30
16	2	30	3.040	17	1.364	14	839	72.4	50–70
17	5	23	1.855	21	989	20	1.200	35,3	20
Mean	5	28.2	2.192	13.8	1.117	11.8	863	62
median	5	29	2.250	13.5	1.065	11	813	62
(range)	(2–9)	(23–30)	(1.080–3.148)	(0–30)	(0–2.855)	(0–30)	(0–2.555)	(0–100)

pre = before treatment (=baseline), y = year; mo = month, w = week, d = day, min = minutes; ^a = mean of every 4 weeks over past 12 weeks;
^b= baseline vs week 24

ISSN: 1129-2377